Malignant hyperpyrexia myopathy.
D000293:Adolescent; D000328:Adult; D000768:Anesthesia, General / Q000009:adverse effects; D001284:Atrophy; D001706:Biopsy; D002648:Child; D002675:Child, Preschool; D005260:Female; D006221:Halothane / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D006984:Hypertrophy; D008297:Male; D008305:Malignant Hyperthermia / Q000139:chemically induced / Q000235:genetics*; D008854:Microscopy, Electron; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D009127:Muscle Rigidity / Q000139:chemically induced; D009132:Muscles / Q000473:pathology; D009135:Muscular Diseases / Q000139:chemically induced / Q000235:genetics* / Q000473:pathology; D009222:Myotonia / Q000139:chemically induced / Q000235:genetics; D009469:Neuromuscular Junction / Q000473:pathology; D013390:Succinylcholine / Q000009:adverse effects / Q000494:pharmacology
D013390:Succinylcholine; D006221:Halothane